Rimegepant is safe and effective for preventing migraines, a phase 2 and 3 trial published in The Lancet reported. The orally administered calcitonin gene–related peptide receptor antagonist is already approved for acute migraine treatment. No oral drugs are currently approved to both prevent and treat migraines.
The 747 adults in the multicenter US study were randomized to 75-mg oral rimegepant or placebo every other day for 12 weeks. During weeks 9 through 12, the rimegepant group had an average 4.3 fewer migraine days per month than during the 4-week observation period at the start of the trial. The placebo group had 3.5 fewer migraine days per month on average. About a third of participants in each group reported adverse events, nearly all of which were mild or moderate.
Slomski A. Oral Rimegepant Safe, Effective for Migraine Prevention. JAMA. 2021;325(8):713. doi:10.1001/jama.2021.0651
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: